We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for bacterial infections, including multi-drug resistant, or MDR, bacterial infections, and rare diseases. Spero’s lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Spero’s partnership directed programs consist of SPR206 and tebipenem HBr, which through the company’s business development efforts, have joint venture relationships supporting their ongoing development. SPR206, is an IV-administered agent being developed as an innovative option to treat MDR Gram-negative bacterial infections, in the hospital setting. Tebipenem HBr, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections, or cUTIs, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. We believe that our novel product candidates will have a meaningful impact on patient health and significant commercial applications for treating MDR infections in hospitals and community settings.
View Top Employees from Spero TherapeuticsWebsite | http://www.sperotherapeutics.com |
Ticker | SPRO |
Revenue | $13 million |
Funding | $306.6 million |
Employees | 94 (94 on RocketReach) |
Founded | 2013 |
Address | 675 Massachusetts Ave 14th Floor, Cambridge, Massachusetts 02139, US |
Phone | (857) 242-1600 |
Technologies |
JavaScript,
HTML,
PHP
+32 more
(view full list)
|
Industry | Biotechnology Research, Drug Manufacturing & Research, Biotechnology, Antibacterial Therapies, Pharmaceuticals, Science and Engineering, Novel Therapeutics, Healthcare, Medical Device, Infectious Disease, Health Care, Therapeutics |
Web Rank | 6 Million |
Keywords | Spero Therapeutics, Current Treatment Of Cuti, Spr206, Everest Medicines License, Sperotherapeutics |
Competitors | Microbiotix, Inc, Ocugen, Otonomy, Inc, Sequella, Inc., Tetraphase Pharmaceuticals |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Spero Therapeutics employee's phone or email?
The Spero Therapeutics annual revenue was $13 million in 2024.
Cristina Larkin is the COO of Spero Therapeutics.
94 people are employed at Spero Therapeutics.
Spero Therapeutics is based in Cambridge, Massachusetts.
The NAICS codes for Spero Therapeutics are [325, 32, 3254, 32541].
The SIC codes for Spero Therapeutics are [28, 283].